February 14, 2017
Moberg Pharma increases full year net profit
Moberg Pharma has posted net profit after tax of SEK 32.7 million (€3.45 million) which is up from SEK 25.5 million last year.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
February 14, 2017
Probi appoints Jörn Andreas as CFO
Probi AB has appointed Jörn Andreas as CFO. Andreas will replace Niklas Brandt who will remain in Probis leadership team as CIO with responsibility for IT infrastructure and Investor relations.
February 14, 2017
Global biosimilars market could see high double digit growth by 2022.
The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry.
February 14, 2017
ViiV Healthcare studies on treating HIV with two drug regimen
ViiV Healthcare, majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, has announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC).
February 14, 2017
Update: Horizon Discovery expands deal with its largest single customer
Horizon Discovery Group has sign a Master Services Agreement with its largest customer, which will be a template for increasing revenue for about £2 million in 2017.
February 14, 2017
European Commission approves Lilly’s and Incyte’s rheumatoid arthritis drug
Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
February 13, 2017
Pharmaceutical grade silica gel market could worth $71.05 million by 2025
The global pharmaceutical grade silica gel market is projected to reach a market size of $71.05 million by 2025.
February 13, 2017
Acacia Pharma’s PONV drug Baremsis meets goals, next step submitting to the FDA
Acacia Pharma Group has made final pivotal Phase 3 study testing amisulpride injection Baremsis, formerly APD421, for patients with post-operative nausea & vomiting (PONV), after getting antiemetic prophylaxis, and now all phases met primary endpoints.
February 13, 2017
Orion finds replacement for its retiring Senior Vice President for Research and Development in Eli Lilly
Orion Group has announced that Dr. Reijo Salonen, M.D., Ph.D., Senior Vice President for Research and Development of the Orion Group and member of the Executive Management Board of the Orion Group will step aside from his current positions as of 21 February 2017.
February 13, 2017
Hikma won exclusive licensing and distribution agreement for pulmonary disease drug
Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orion Corporation of Finland (Orion), for its new Easyhaler combination product, a dry powder inhaler (DPI) of budesonide and formoterol, for the treatment of asthma and chronic obstructive pulmonary disease (COPD).